Skip to content

Evaluation the effectiveness of pomegranate and spearmint (Vomigramint) syrup on CINV

Evaluation the effectiveness of a mixture-syrup based on pomegranate and spearmint (Vomigramint), compared with placebo, on Chemotherapy induced nausea and vomiting (CINV) in breast cancer

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20171118037516N1
Enrollment
60
Registered
2018-03-06
Start date
2018-02-19
Completion date
Unknown
Last updated
2018-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: nausea and vomiting. Condition 2: Breast cancer. Nausea and vomiting Malignant neoplasm of breast of unspecified site, female

Interventions

Intervention 1: Intervention group: 30 patients with breast cancer, using syrup (250 cc bottle) contains of pomegranate juice and spearmint extract (with proportion of 2/1), produced with Persian medi

Sponsors

Sari University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: More than 18 years-old aging Documentary report for Breast cancer At least one session of chemotherapy is done prior to intervention Taking similar and one-day chemotherapy regimen At least two sessions of chemotherapy is proceeding History of any level of CINV (qualitative or quantative), despite taking routine anti-emetic drugs.

Exclusion criteria

Exclusion criteria: Total or upper abdomen radiotherapy, accompanying with chemotherapy simultaneously Consumption therapeutic dosage of anti-coagulant agents History of coagulopathic disorders Taking anti- emetic drugs or methods, except those permitted drugs in this study History of hypersensitivity to pomegranate or spearmint Pomegranate or spearmint consumption during one week prior to intervention Suffering from other cancers or metastatic breast cancer simultaneously Having other problems or diseases causing nausea( e.g. Hypertension, Liver or Renal failure, Diabetes mellitous , Constipation )

Design outcomes

Primary

MeasureTime frame
Severity of nausea. Timepoint: Three days before intervention, One day after intervention, five days after intervention. Method of measurement: Visual analogue scale.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyede Sedighe Yousefi

Sari University of Medical Sciences

s.yousefi@mazums.ac.ir+98 11335430813

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026